Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2014 by Mundipharma K.K.
Information provided by (Responsible Party):
Mundipharma K.K. Identifier:
First received: January 22, 2013
Last updated: February 13, 2014
Last verified: February 2014

Phase I portion:

To confirm safety and tolerability in recurrent/refractory peripheral T-cell lymphoma patients during repeated oral administration of forodesine 300 mg twice daily (600 mg/day) for 28 days, and determine the recommended dose. Also, to evaluate pharmacokinetics.

Phase II portion:

To evaluate the efficacy, safety, and pharmacokinetics of the recommended dosage regimen determined in the phase I portion. The primary efficacy endpoint shall be objective response rate (ORR).

Condition Intervention Phase
Recurrent or Refractory PTCL
Drug: forodesine hydrochloride
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients

Resource links provided by NLM:

Further study details as provided by Mundipharma K.K.:

Primary Outcome Measures:
  • Objective response rate (ORR) based on evaluation by image assessment committee [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 49
Study Start Date: January 2013
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Single Arm
Drug: forodesine hydrochloride 600 mg / body/day (3 x 100 mg capsules twice daily)
Drug: forodesine hydrochloride


Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Japanese patients at least 20 years of age.
  • Patients histologically diagnosed with peripheral T-cell lymphoma by pathological diagnosis of biopsied lesion. In this study, peripheral T-cell lymphoma is defined as the following mature T-cell/NK-cell neoplasms found in the 4th edition of the WHO Classification.
  • Recurrent/refractory patients with a treatment history of at least one regimen.
  • Patients with an enlarged lymph node or extranodal mass lesion clearly measurable in two perpendicular directions and greater than 1.5 cm in maximum diameter on computed tomography performed.
  • Patients expected to survive for at least 3 months.
  • ECOG PS 0-1.
  • Patients with adequate hemopoietic efficacy, liver and kidney function.
  • Patients from whom written consent has been obtained prior to study initiation.

Exclusion Criteria:

  • Patients who received a chemotherapy agent or a high dose of a systemic adrenocorticosteroid within 21 days prior to initial administration of the study drug.
  • Patients who received radiation therapy, phototherapy, or electron beam therapy within 21 days prior to initial administration of the study drug.
  • Patients who received another study drug within 28 days prior to initial administration of the study drug.
  • Patients who received antibody therapy within 100 days prior to initial administration of the study drug.
  • Patients with a history of allogeneic hematopoietic stem cell transplantation. Or patients with a history of autologous hematopoietic stem cell transplantation within 100 days prior to initial administration of the study drug.
  • Patients with cerebral metastasis or central nervous system lesion or a past history.
  • Patients with active multiple primary cancer. Or patients with a history of a malignant neoplasm other than peripheral T-cell lymphoma within the past 5 years.
  • Patients with severe cardiovascular disease.
  • Patients with congenital long QT syndrome.
  • Patients with QTcF >0.48 sec.
  • Patients positive for HBs antigen, HCV antibody or HIV antibody on immunological investigation. Or patients positive for either HBc antibody or HBs antibody, and showing DNA more than sensitivity in HBV-DNA assay.
  • Patients positive for CMV antigen on immunological investigation.
  • Patients with infectious disease requiring treatment consisting of intravenous administration of antibacterial agent, fungicide, or antiviral drug.
  • Patients with interstitial pneumonia or pulmonary fibrosis, or patients judged to have insufficient pulmonary function.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01776411

Nagoya Daini Red Cross Hospital Recruiting
Nagoya, Aichi, Japan, 466-8650
Contact: Toshiki Uchida, MD, PhD    +81-52-832-1121      
Principal Investigator: Toshiki Uchida, MD, PhD         
National Hospital Organization Nagoya Medical Center Recruiting
Nagoya, Aichi, Japan, 460-0001
Contact: Hirokazu Nagai, MD, PhD    +81-52-951-1111      
Principal Investigator: Hirokazu Nagai, MD, PhD         
National Cancer Center Hospital East Recruiting
Kashiwa, Chiba, Japan, 277-8577
Contact: Kunihiro Tsukasaki, MD, PhD    +81-4-7133-1111      
Principal Investigator: Kunihiro Tsukasaki, MD, PhD         
National Hospital Organization Shikoku Cancer Center Recruiting
Matsuyama, Ehime,, Japan, 791-0280
Contact: Isao Yoshida, MD, PhD    + 81-89-999-1111      
Principal Investigator: Isao Yoshida, MD, PhD         
Gunma University Hospital Recruiting
Maebashi, Gunma, Japan, 371-8511
Contact: Norifumi Tsukamoto, MD, PhD    +81-27-220-8529      
Principal Investigator: Norifumi Tsukamoto, MD, PhD         
National Hospital Organization Hokkaido Cancer Center Recruiting
Sapporo, Hokkaido, Japan, 003-0804
Contact: Mitsutoshi Kurosawa, MD, PhD    +81-11-811-9111      
Principal Investigator: Mitsutoshi Kurosawa, MD, PhD         
Hyogo Cancer Center Recruiting
Akashi, Hyogo, Japan, 673-8558
Contact: Tohru Murayama, MD, Ph.D    +81-78-929-1151      
Principal Investigator: Tohru Murayama, MD, Ph.D         
Tokai University Hospital Recruiting
Isehara, Kanagawa, Japan, 259-1143
Contact: Kiyoshi Ando, MD    +81-463-93-5083      
Principal Investigator: Kiyoshi Ando, MD         
Tohoku University Hospital Recruiting
Sendai, Miyagi, Japan, 980-8574
Contact: Kenichi Ishizawa, MD, PhD    +81-22-717-7772      
Principal Investigator: Kenichi Ishizawa, MD, PhD         
Osaka University Hospital Recruiting
Suita, Osaka, Japan, 565-0871
Contact: Hirohiko Shibayama, MD, Ph.D    +81-6-6879-3871      
Principal Investigator: Hirohiko Shibayama, MD, Ph.D         
Shimane University Hospital Recruiting
Izumo, Shimane, Japan, 693-8501
Contact: Junji Suzumiya, MD, PhD    +81-853-23-2111      
Principal Investigator: Junji Suzumiya, MD, PhD         
Tochigi Cancer Center Recruiting
Utsunomiya, Tochigi, Japan, 320-0834
Contact: Tohru Izumi, MD,PhD    +81-286- 58-5669      
Principal Investigator: Tohru Izumi, MD,PhD         
National Cancer Center Hospital Recruiting
Chuo, Tokyo, Japan, 104-0045
Contact: Kensei Tobinai, MD, PhD    +81-3-3542-2511      
Principal Investigator: Kensei Tobinai, MD, PhD         
The Cancer Institute Hospital Japanese Foundation for Cancer Research Recruiting
Koto, Tokyo, Japan, 135-8550,
Contact: Kiyohiko Hatake, MD, PhD    +81-3-3520-0111      
Principal Investigator: Kiyohiko Hatake, MD, PhD         
University of Fukui Hospital Recruiting
Fukui, Japan, 910-1193
Contact: Takahiro Yamauchi, MD, Ph.D, FACP    +81-776-61-3111      
Principal Investigator: Takahiro Yamauchi, MD, Ph.D, FACP         
Fukuoka University Hospital Recruiting
Fukuoka, Japan, 814-0180
Contact: Kazuo Tamura, MD, PhD    +81-92-801-1011      
Principal Investigator: Kazuo Tamura, MD, PhD         
National Hospital Organization Kyushu Cancer Center Recruiting
Fukuoka, Japan, 811-1395
Contact: Naokuni Uike, MD    +81-92-541-3231      
Principal Investigator: Naokuni Uike, MD         
Imamura Bun-in Hospital Recruiting
Kagoshima, Japan, 890-0064
Contact: Atae Utsunomiya,, MD, PhD    +81-99-251-2221      
Principal Investigator: Atae Utsunomiya, MD, PhD         
National Hospital Organization Kumamoto Medical Center Recruiting
Kumamoto, Japan, 860-0008
Contact: Michihiro Hidaka, MD, PhD    +81-96-353-6501      
Principal Investigator: Michihiro Hidaka, MD, PhD         
University Hospital, Kyoto Prefectural University of Medicine Recruiting
Kyoto, Japan, 602-8566
Contact: Masafumi Taniwaki, MD, PhD    +81-75-251-5651      
Principal Investigator: Masafumi Taniwaki, MD, PhD         
Okayama University Hospital Recruiting
Okayama,, Japan, 700-8558
Contact: Yoshinobu Maeda, MD, PhD    +81-86-233-7151      
Principal Investigator: Yoshinobu Maeda, MD, PhD         
Sponsors and Collaborators
Mundipharma K.K.
Principal Investigator: Kensei Tobinai, MD,PhD National Cancer Center Hospital
  More Information

No publications provided

Responsible Party: Mundipharma K.K. Identifier: NCT01776411     History of Changes
Other Study ID Numbers: FDS-J02
Study First Received: January 22, 2013
Last Updated: February 13, 2014
Health Authority: Japan: Ministry of Health, Labor and Welfare

Additional relevant MeSH terms:
Lymphoma, T-Cell
Lymphoma, T-Cell, Peripheral
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms by Histologic Type processed this record on November 25, 2014